The research company Irlab Therapeutics was presented by CFO Gustaf Albèrt at the Life Science Day in Gothenburg on Wednesday.

Irlab is developing a portfolio of treatments for all stages of Parkinson's disease. The number of affected individuals currently stands at 11 million and is expected to double over the next 15-20 years.

The company has five drug candidates:

* Mesdopetam, IRL790, is being developed for the treatment of levodopa-induced dyskinesias, has completed phase 2b, and is in preparation for phase 3.
* Pirepemat, IRL752, is in phase 2b and is being evaluated for its effect on fall frequency in Parkinson's patients.
* IRL757, a compound being developed for the treatment of apathy in neurodegenerative diseases, is in phase 1b. Irlab is collaborating here with MSRD and Otsuka.
* IRL942 and IRL1117 are in the preclinical phase and are being developed towards phase 1 studies.

Irlab is working to secure funding for the phase 3 study of Mesdopetam, explains Gustaf Albèrt, adding that the company is financed well into the second half of 2026.

Regarding Pirepemat, the company faces a strategic decision on how to proceed, and a decision is expected sometime during 2026, says Gustaf Albèrt.

Irlab sees significant sales potential for all five drug candidates.

- We see blockbuster potential in all five drug candidates, says Gustaf Albèrt. Blockbuster means that a drug generates at least 1 billion dollars in sales per year.

In the fourth quarter of 2025, Irlab had revenues of 14.7 million kronor and an operating loss of 21.9 million kronor. Liquid assets amounted to 82 million kronor at year-end.